Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MQU10 is a microbiome-based therapeutic candidate developed by GenieBiome (G-Nii) in collaboration with the Chinese University of Hong Kong (CUHK) and the Microbiota I-Center (MagIC). It is a probiotic formula designed for microbiome modulation to address mood disorders in adults. The development program leverages the gut-brain axis, aiming to improve mental health outcomes through the restoration or alteration of gut microbial composition. As of 2024, MQU10 is in Phase 1 clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MQU10.